An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C-IV non-squamous NSCLC.

Li S, Du F, Leng C, Dou J, Shi J, Zhang Y, Lu F, Wang Q

Open source

DOI
10.3389/fimmu.2026.1854773
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1854773,
  title = {An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C-IV non-squamous NSCLC.},
  author = {Li S and Du F and Leng C and Dou J and Shi J and Zhang Y and Lu F and Wang Q},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1854773},
  url = {https://doi.org/10.3389/fimmu.2026.1854773}
}

RIS

TY  - JOUR
TI  - An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C-IV non-squamous NSCLC.
AU  - Li S
AU  - Du F
AU  - Leng C
AU  - Dou J
AU  - Shi J
AU  - Zhang Y
AU  - Lu F
AU  - Wang Q
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1854773
UR  - https://doi.org/10.3389/fimmu.2026.1854773
ER  - 

APA

S, L., F, D., C, L., J, D., J, S., Y, Z., F, L., & Q, W. (2026). An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C-IV non-squamous NSCLC.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1854773

Source records